Peak6 Investments LLC Mirati Therapeutics, Inc. Transaction History

Peak6 Investments LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $839,925 - $1.25 Million	20,003 New	20,003 $1.18 Million
Q2 2023 Aug 11, 2023	SELL	$36.13 - $49.49 $83,893 - $114,915	-2,322 Reduced 35.72%	4,178 $150,000
Q1 2023 May 12, 2023	SELL	$36.54 - $54.26 $263,343 - $391,051	-7,207 Reduced 52.58%	6,500 $241,000
Q4 2022 Feb 10, 2023	SELL	$41.27 - $98.62 $200,365 - $478,800	-4,855 Reduced 26.16%	13,707 $621,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $714,952 - $1.04 Million	-12,016 Reduced 39.3%	18,562 $1.3 Million
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $789,935 - $1.79 Million	20,172 Added 193.85%	30,578 $2.05 Million
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $788,982 - $1.57 Million	10,406 New	10,406 $856,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.